Predictors of fulvestrant long-term benefit in hormone receptor-positive/HER2 negative advanced breast cancer.

Nonetheless, patients with ≤ 3 metastatic sites (OR: 1.6, CI 95% 0.2;14.9; p value: 0.71), patients with Luminal A tumors (OR 1.4, CI 95% 0.4; 4.8; p = 0.563), and patients treated with < 3 previous lines of therapy (OR 1.7, CI 95% 0.4–5; p = 0.390) had a higher probability to be alive and progression-free at 18 months as compared with patients with > 3 metastatic sites, with luminal B tumors and treated with ≥ 3 lines, respectively, although these results did not reach statistical significance.

also in 111,027 other papers